MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Revvity Inc

Geschlossen

BrancheGesundheitswesen

96.79 -0.75

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

96.16

Max

97.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.6M

47M

Verkäufe

-21M

699M

KGV

Branchendurchschnitt

50.057

88.032

EPS

0.4

Dividendenrendite

0.29

Gewinnspanne

6.675

Angestellte

11,000

EBITDA

-14M

181M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+14.15% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.29%

2.26%

Nächstes Ex-Dividendendatum

16. Jan. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5.8M

11B

Vorheriger Eröffnungskurs

97.54

Vorheriger Schlusskurs

96.79

Nachrichtenstimmung

By Acuity

12%

88%

15 / 374 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Dez. 2025, 22:20 UTC

Wichtige Markttreiber

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. Dez. 2025, 17:31 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. Dez. 2025, 16:30 UTC

Wichtige Markttreiber

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. Dez. 2025, 15:19 UTC

Wichtige Markttreiber

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. Dez. 2025, 15:17 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. Dez. 2025, 14:37 UTC

Wichtige Markttreiber

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. Dez. 2025, 21:13 UTC

Akquisitionen, Fusionen, Übernahmen

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. Dez. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. Dez. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. Dez. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. Dez. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. Dez. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. Dez. 2025, 17:16 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. Dez. 2025, 17:00 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. Dez. 2025, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. Dez. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. Dez. 2025, 15:02 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. Dez. 2025, 14:40 UTC

Akquisitionen, Fusionen, Übernahmen

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. Dez. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. Dez. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. Dez. 2025, 13:01 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. Dez. 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. Dez. 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. Dez. 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. Dez. 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. Dez. 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

14.15% Vorteil

12-Monats-Prognose

Durchschnitt 111.22 USD  14.15%

Hoch 123 USD

Tief 100 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

5

Buy

5

Halten

0

Sell

Stimmung

By Acuity

15 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat